1 Followers
25 Following
chaitanyag11

chaitanyag11

Transcatheter Embolization and Occlusion Devices Market Outlook And Global Insights

Transcatheter embolization and occlusion refers to passage or insertion of a synthetic embolus through a fine catheter in the blood vessel to obstruct the blood flow in particular area of the body. Transcatheter embolization is a minimally invasive procedure performed as a part of interventional radiology to restrict blood supply to tumors.

Transcatheter Embolization and Occlusion Devices Market Outlook And Global Insights

Transcatheter embolization and occlusion refers to passage or insertion of a synthetic embolus through a fine catheter in the blood vessel to obstruct the blood flow in particular area of the body. Transcatheter embolization is a minimally invasive procedure performed as a part of interventional radiology to restrict blood supply to tumors. Synthetic materials known as embolic agents, in some cases, are coated with chemotherapeutic drugs that perform dual action of blocking the blood supply as well as inducing cytotoxicity to attack the tumor in several ways. Moreover, this procedure is also employed to control or prevent abnormal bleeding, eliminate abnormal connections between arteries and veins as well as to treat aneurysms, which refers to formation of a bulge or a sac in weak arterial wall.

Transcatheter embolization is a less invasive and highly efficient way to control bleeding as compared to open invasive surgical procedures. Catheter embolization is considered to be the first line of treatment in gastrointestinal bleeding. This process can be performed alone or combined with other treatments such as surgery or radiation. The process is initiated with the help of x-ray imaging to visualize the blood vessel, after which an interventional radiologist inserts a catheter to the skin into the desired blood vessel and advanced to the treatment site. Among females, this method provides an excellent alternative to hysterectomy to shrink and control heavy menstrual bleeding by interrupting the blood supply caused due to uterine fibroid tumors.

Market Dynamics

Increasing demand for minimally invasive surgical procedures over conventional open surgeries is expected to propel growth of transcatheter embolization and occlusion devices market. This shift is a result of advantages offered by minimally invasive procedures over open surgeries that includes significantly low blood loss, low recovery time, low surgical time, reduced probability of errors, and others. For instance, according to a retrospective review published by Department of Surgery, John Hopkins Hospital, in 2014, it suggested that the complication and error rates for hysterectomy was 4.69% and 6.64% in catheter embolization and open surgical procedures, respectively. Moreover, rising incidence of venous malformations leading to vascular anomalies is also an important factor contributing significantly to growth of the market. For instance, according to the International Society for Auricular Reconstruction, 2017, the incidence of venous malformations was reported to be 1-4% of the total world population, without any predilection in the sex. However, practice of transcatheter embolization procedures without following FDA guidelines leading to increased hospital readmissions and requirement of expertise to perform the procedures is expected to hinder the market growth. For instance, according to a research survey conducted by University of Michigan Health System, in 2015, reported that 27% of increase in major post-operative complications were reported among patients that took up catheter embolization for the treatment of fibroid tumors.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1683

Regional Insights

On the basis of region, the global transcatheter embolization and occlusion devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global transcatheter embolization and occlusion devices market and is expected to retain its dominance over the forecast period, owing to large population suffering from fibroid tumor, arteriovenous malformations (AVM), and other diseases. According to the American Association of Neurological Surgeons 2017, the prevalence of arteriovenous malfunctions (AVM) is estimated at 18 people per 100,000 population in the U.S. Moreover, the AVM is reported to be the second most identifiable cause for subarachnoid hemorrhage. Furthermore, leading players in the market are introducing novel products in the market and this is also expected to aid in growth of the market in the region. For instance, in September 2017, Medtronic Plc expanded its embolization product portfolio with the introduction of Concerto 3D detachable system in the U.S. and Europe that can be used in arterial and venous embolization.

Furthermore, Asia Pacific is expected to witness a significant growth in the market, which is attributed to increasing medical tourism in emerging economies such as Japan, India, and ASEAN countries that provides high quality medical services at low costs. According to International Medical Travel Journal, Indian hospitals served 460,000 international patients in 2015–2016 for various surgical procedures.

Competitive Insights

Key players operating in the global transcatheter embolization and occlusion devices market include Boston Scientific Corporation, Terumo Corporation, Cook Medica, DePuy Synthes, Edwards, Eisai, Medtronic Plc, Merit Medical System, Stryker Corporation, St. Jude Medical, Pfizer, Inc., Sirtex Medical, Nordian, and others. Market players are focused on providing technologically advanced products, to sustain their position in the competitive market. For instance, in January 2018, Johnson & Johnson’s Cerenovous division introduced Galaxy G3 Mini embolic coil to remove clots from brain post ischemic strokes.

Click To Reading More On Transcatheter Embolization and Occlusion Devices Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Medical Ceramics Market Modest Situation Among the Top Manufacturers With Sales, Revenue

The global medical ceramics market is estimated to be valued at US$ 3,835.7 million in 2017 and is expected to witness a CAGR of 6.1% over the forecast period (2017–2025).

Medical ceramics are products that are biocompatible and aid in repairing or replacing musculoskeletal hard connective tissues. The ceramic materials used for medical purposes is not the same as porcelain type ceramic materials. Medical ceramic is closely related to either the body's own materials or is extremely durable metal oxides that are primarily used in dental and orthopedic applications as implants or replacements. Ceramic material with high-purity, high-density, and fine-grained polycrystalline alumina is used for load-bearing hip prostheses. Furthermore, other bio-ceramic implants can serve as porous media to support the ingrowth of new bone tissue such as materials that bio-react with bone, or as scaffolds that are completely resorbed after establishing a template for tissue growth. Increasing prevalence of joint-related diseases and dental problems had led to development of new technologies and methods. For instance, in 2016, Glidewell Laboratories launched a new line of dental bone grafting products under the brand name Newport Biologics. This is expected to fuel adoption of medical ceramics over the forecast period.

Rising number of medical procedures involving dental implants, orthopedic implants, and others is one of the major factors driving growth of this market. According to the European Commission, 2015, around 800,000 hip procedures were carried out every year in Europe, costing around US$ 1.5 billion. The market growth is also driven by development of novel product varieties with higher mechanical strengths and flexibility. Due to their excellent frictional properties, technical ceramics are gaining popularity in endo-prosthetics. Increasing trauma cases due to falls and road accidents, requires medical intervention (orthopedics), thus, augmenting the need for medical ceramics products. In 2012, according to the National Institute of Health, knee is the most commonly injured joint by adolescent athletes with an estimated 2.5 million sports-related injuries presenting to emergency departments, annually in the U.S. This number is expected to increase significantly over the forecast period.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1261

Ceramic Materials are the combination of thermal and physical qualities which are used for various medical applications for the repair and reconstruction of human body parts. This employed majorly in dental and orthopedic applications, mainly as implants or replacements. The inherent brittleness of traditional ceramics has limited their ability to compete with ductile metals and polymers for technical applications. However, over the last 100 years innovative techniques in the fabrication of ceramics have led to their use as high-tech materials. Inert bioceramic, such as ZrO2 and Al2O3, have inherently low levels of reactivity compared with other materials such as polymers and metals as well as surface reactive or resorbable ceramics and they are expected to be non-toxic, non-allergenic, and non-carcinogenic for a life-time in a human bod. This led to the early adoption of the most recent generation of instruments using an established technology in the hospitals.

Manufacturers are focusing on developing new ceramics to be used in various medical applications. For instance, in March 2017, CeramTec launched its newly developed dental ceramic, Zirconium Oxide Bright, at International Dental Show (IDS) in Cologne, Germany. The material combines high translucency and high strength and is suitable for all dental prostheses treatments.

North America market accounted for the largest market share, followed by Europe in 2016. This is owing to high usage of implantable medical devices, furthermore, rise in number of osteoporotic fractures in the U.S. and presence of relatively large number of medical device manufacturers in this region is expected to be a factor for growth of the medical ceramics market in this region. For instance, according to the National Osteoporosis Foundation (NOF), over 1.3 million osteoporotic fractures occur each year in the U.S. The market in Asia Pacific and Latin America is also expected to witness substantial growth. This is owing to rise in medical tourism for dental and orthopedic procedures. According to the study by Far International, 2016, the knee replacement surgery costs around US$ 40,000, whereas the costs in Colombia is only US$ 15,000.

Some of the key players in medical ceramics market are CoorsTek Medical, H.C. Starck GmbH, Tosoh Corporation, Noritake Co., Ltd., 3M ESPE, Morgan Advanced Materials plc, Ceramtec, Pl Ceramic GmbH, Lithoz, and Kyocera Corporation.

Click To Reading More On Medical Ceramics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Porphyria treatment Market Major Players SWOT Analysis 2019

The most common tests used for porphyrias diagnosis are measurements of substances such as porphyrin precursors and porphyrins, in blood plasma, red blood cells, feces, and urine. Measuring enzymes in cells and mutations in DNA is useful for confirmation and family studies.

Metastatic Osteosarcoma Treatment Market 2019-2026: Instruments, Consumables

Osteosarcoma or bone cancer is a type of cancer were bone tissues show an abnormal growth. Osteosarcoma that spreads from initially affected area to distant site is known as metastatic osteosarcoma.

Metastatic Osteosarcoma Treatment Market 2019-2026: Instruments, Consumables

Osteosarcoma or bone cancer is a type of cancer were bone tissues show an abnormal growth. Osteosarcoma that spreads from initially affected area to distant site is known as metastatic osteosarcoma. Metastatic osteosarcoma often spreads to lungs, whereas less commonly spreads to other bones, brain or other organs. Symptoms of metastatic osteosarcoma varies based on the location of tumor, for example bone pain, bone fracture, swelling, redness, limping, and limited joint movement. If the tumor spreads to the lungs the symptoms include chest pain, shortness of breath, cough with blood, chronic coughing or wheezing. Diagnostic tests for metastatic osteosarcoma includes CT-scan, MRI, X-ray, PET scan, biopsy, and bone scan. Treatment of metastatic osteosarcoma involves surgery, radiation, chemotherapy, biological therapy or a combination of these treatments. Combinational treatment also known as multi-modality treatment is more preferred by medical practitioners to increase treatment outcomes or to prolong survival.

Metastatic Osteosarcoma Treatment Market – Drivers

Increasing drug pipeline for malignant bones and soft tissue (Ewing Sarcoma) cancer is expected to drive growth of metastatic osteosarcoma treatment market. For instance, in 2017, Merck & Co., Inc., studies the effects of Pembrolizumab (MK-3475) in patients with relapsed or metastatic osteosarcoma and reported that these patient are not eligible for curative surgery. Currently, study is in phase II clinical trial and is expected to be marketed in 2023. Moreover, Novartis entered into phase II clinical trials for pazopanib for treatment of metastatic osteosarcoma as of March 2018.

Emerging new therapies for metastatic osteosarcoma treatment will further propel growth of the market. For instance, clinical trials for immunotherapy-based drugs and targeted drug therapy is expected to be a preferred option in the near future, owing to less side-effects. The immune therapy drug called immune checkpoint inhibitors can recognize and attack cancer cells exhibiting better outcomes for other cancer types and also studies have showed it is also effective for osteosarcoma treatment. Moreover, engineered monoclonal antibodies are used to stop cancer growth by hampering new blood vessel formation or to inhibit tumor cells by targeting mTOR protein. For instance, Aadi, LLC studies Nivolumab (Opdivo) in combination with ABI-009 (Nab-rapamycin, the mTOR inhibitor) for potential anti-tumor activity for Ewing Sarcoma. The study is in phase II clinical trial, which is expected to complete by 2020.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1578

In case of pediatric osteosarcoma, around 35% of patient fail first-line of therapy, leading to recurrence in metastatic osteosarcoma in lungs. Therefore, development of novel drugs for treatment of lung cancer, due to metastatic osteosarcoma will also contribute to growth of the metastatic osteosarcoma treatment market. For instance, in 2013, Elesion Pharmaceuticals LLC, a pharmaceutical company developing life-saving therapeutics for rare cancers, entered into phase II clinical trials for Inhaled Lipid-complexed Cisplatin (ILC), a novel sustained release formulation of cisplatin in a nanoscale lipid based complex, for pediatric patients with osteosarcoma metastases for lungs. Additionally, inorganic marketing strategies adopted by metastatic osteosarcoma drug market players is expected to aid in the market growth. For instance, in the same year, Inhaled Lipid-complexed Cisplatin orphan drug designation by European Medicines Agency for the treatment of osteosarcoma. Furthermore, in 2015, company entered in partnership with Intelgen Limited, a Hong Kong-based biopharmaceutical company, for specialized novel anti-cancer drug development and commercializing ILC in Chinese market. Moreover, in 2014, Oncolytics Biotech, examined safety and efficacy of Reolysin for the treatment of bone and soft tissue sarcoma metastatic for lungs.

Metastatic Osteosarcoma Treatment Market – Restrain

Growth of the metastatic osteosarcoma treatment market can be hindered by availability of alternative therapies such as new forms of radiation therapy (intensity-modulated radiation therapy, stereotactic radiosurgery or conformal proton beam therapy). Moreover, stringent approval policies for varies drug therapies is also expected to adversely affect growth of the market.

Metastatic Osteosarcoma Treatment Market - Regional Analysis

Based on geography, the metastatic osteosarcoma treatment market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the global metastatic osteosarcoma treatment market over the forecast period, owing to increasing research and developmental activities and increasing pipeline products by market players such as Novartis and Merck & Co. Inc. Moreover, high osteosarcoma incidence contribute to the share. For instance, in 2016, American Society of Clinical Oncology (ASCO), estimated 1,000 people to be diagnosed with osteosarcoma each year. However, Asia Pacific is expected to witness fast growth in metastatic osteosarcoma treatment market, due to increasing incidence of osteosarcoma in the region.

Metastatic Osteosarcoma Treatment Market – Competitor

Key players operating in the metastatic osteosarcoma treatment market are Mylan Laboratories Limited, Actavis Inc., Alvogen Inc., Gland Pharma Limited, Sagent Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., and Luitpold Pharmaceuticals Inc.

Click To Reading More On Metastatic Osteosarcoma Treatment Market 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Porphyria treatment Market Major Players Swot Analysis 2019

The most common tests used for porphyrias diagnosis are measurements of substances such as porphyrin precursors and porphyrins, in blood plasma, red blood cells, feces, and urine. Measuring enzymes in cells and mutations in DNA is useful for confirmation and family studies. Though, no cure is available for porphyria, there is treatment for each type of the disease. Treatment depends on the type and severity of the disorder and can involve treating with heme, giving medicines to relieve the symptoms, or drawing blood. Drugs like Thorazine, Chlorpromazine, Panhematin and Hemin can be used to treat symptoms of porphyria. Panhematin (Recordati Rare Diseases) is used for treating acute porphyrias. It is a lyophilized form of alkaline heme that has to be reconstructed immediately before administration and should be infused into a large peripheral vein. As per American Porphyria Foundation, Panhematin is the only commercially available heme therapy in the U.S.

Porphyria Cutanea Tarda (PCT) is the most common and treatable form of porphyria and occurs, due to deficiency of the enzyme, uroporphyrinogen decarboxylase (UROD). PCT is a genetic disorder, however, some people have a genetic (autosomal dominant) deficiency of UROD that results in growth of PCT. Most people with the inherited enzyme deficiency remain latent and show no symptoms. Various environmental factors can impact the occurrence and severity of symptoms of porphyria. Smoking, alcohol, change in hormones levels, stress, certain drugs, and dieting or fasting can trigger the signs and symptoms of some forms of porphyrias. Moreover, exposure to sunlight severely damages the skin of people with cutaneous porphyrias. However, low incidence rates of porphyria can negatively impact the porphyria treatment market

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1706

Porphyria treatment Market Regional Insights

Regional segmentation of porphyria treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe are expected to generate significant revenue share in the porphyria treatment market, owing to high presence of major industry players launching new products and conducting R&D for novel product development. For instance, in April 2018, Alnylam Pharmaceuticals, the leading RNAi therapeutics company, presented new results from the Phase 1 and Phase 1/2 open-label extension (OLE) studies of givosiran (RNAi therapeutic) targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. These results were presented at the European Association for the Study of the Liver (EASL), France. According to American Porphyria Foundation 2017, all forms of porphyria affect less than 200,000 people in the U.S. In Europe, the prevalence of the porphyria cutanea tarda (PCT), is 1 in 10,000, erythropoietic protoporphyria (EPP), is around 1 in 50,000 to 75,000, and acute intermittent porphyria (AlP), is about 1 in 20,000. Congenital erythropoietic porphyria (CEP) is very rare with prevalence rate of 1 in 1,000,000 or fewer.

Porphyria Treatment Market Competitive Landscape

Key players operating in the porphyria treatment market include ACON Laboratories, Inc., Bio-Rad Laboratories, Inc., Dahaner, Hoffmann-La Roche Ltd, Siemens AG, ARKRAY, Inc., and  Sysmex Corporation. Industry players are working towards development of new treatments for the disease.

Porphyria is an inherited rare disorder that affects the nervous system or skin and may cause abdominal pain. Cells of porphyria patients are unable to change body chemicals called porphyrins and its precursors into heme, the substance responsible for blood color. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the exact rates of porphyria are unknown and vary globally. For instance, porphyria cutanea tarda is most common in the U.S., and variegate porphyria is frequent in South America. Some porphyrias such as erythropoietic protoporphyria, hepatoerythropoietic porphyria, and congenital erythropoietic porphyria occur when an individual receives two abnormal genes, one from each parent. The chances of an individual passing the abnormal gene or genes to the next generation depends on the type of porphyria. Acute porphyrias affects the nervous system and abdomen. Its attacks develop over hours or days and can last up to several weeks. Cutaneous porphyrias affects the skin. According to the American Porphyria Foundation, acute porphyria affects around 1 to 2 individual per 100,000. High incidence rate was reported in South Africa and Sweden. The foundation promotes comprehensive care necessary for treating individuals with Porphyria. It promotes the disease awareness, reduce the stigma associated with porphyria through physician education, and provides support for those affected. The foundation also organized the Porphyria Awareness Week in April 2018, 21-28.

Click To Reading More On Porphyria Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Vagus Nerve Stimulators Market - 2019 Global Strategic Business Report

Vagus nerve stimulation (VNS) is a medical treatment in which electric impulses are delivered to vagus nerve for the management and treatment of various types of diseases including epilepsy and depression. Vagus nerve stimulators are devices used to stimulate the vagus nerve with electrical impulses.

Light blue tube Phlebotomy Market - increasing demand with Industry Professionals

The process of drawing blood from veins is known as phlebotomy. The procedure, also known as venipuncture, is primarily performed by specialists called phlebotomists. Medical laboratory scientists, doctors, and nurses often perform phlebotomy process as well.

Light blue tube Phlebotomy Market - increasing demand with Industry Professionals

The process of drawing blood from veins is known as phlebotomy. The procedure, also known as venipuncture, is primarily performed by specialists called phlebotomists. Medical laboratory scientists, doctors, and nurses often perform phlebotomy process as well. Phlebotomy is carried out for a range of reasons such as blood donations, medical testing, and research.  Light blue top tubes are used for performing coagulation tests. Blood clotting or coagulation is the method by which blood changes its form. It forms a lump known as clot. This process leads to hemostasis, and prevent the blood loss from the body. The course of action of coagulation includes activation, bonding, and accumulation of platelets in addition to deposition and development of fibrin. Disorder related to clotting can result in thrombosis or hemorrhage. Phlebotomy tubes with light blue stoppers primarily contain two additives: sodium citrate (3.2% or 3.8%) and Citrate, theophylline, adenosine, dipyridamole) or CTAD. The citrate acts as an anticoagulant. It binds the calcium present in the blood that is required for clotting. As the additive gives a whole blood sample that is plasma and red blood cells, the light blue phlebotomy tubes have buffered tri-sodium citrate solution as well.

Various tests are performed using the light blue phlebotomy tube. Some of them are Partial Thromboplastin Time (PTT), Fibrin degradation products (FDP), Thrombin Time (TT), Prothrombin Time (PT), Fibrinogen, and D-dimer. The global light blue tube phlebotomy market is expected to swell at a considerable rate in the near future. Rise in health awareness has resulted in the increase in blood diagnostic tests; particularly coagulation tests owing to mounting incidences of low platelet count, increased prevalence of liver diseases, as well as growth in number of surgeries are factors that will be responsible for the growth of light blue tube phlebotomy market.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/143

An important factor for using light blue top tubes is the amount of blood extracted in the tubes. The tubes should be filled to the brim for obtaining accurate results. The blood should continue to flow from the patient’s body into the tube until the tube is full and the blood flow ceases. If the blood is extracted through a syringe, the optimum level (as marked in most of the light blue top tubes) should be maintained. This factor is important because light blue top tubes are used for coagulation tests which require 9:1 blood to anticoagulant ratio.

Asia Pacific to be growth engine for global light blue tube phlebotomy market

Increasing incidence of blood related diseases is projected to create a highly conducive environment for growth of the global light blue tube phlebotomy market. According to Center for Disease Control and Prevention, almost 1 to 2 people could be affected by DVT/PE. Pulmonary embolism (PE) typically occurs when a blood clot known as a deep vein thrombosis (DVT), habitually in the leg, moves to the lungs and form a lump, thereby blocking a blood vessel. It results into to low oxygen levels in the blood. It can harm the lung and may cause heart failure as well. Therefore, a blood coagulation test is usually suggested to patients with a history of such diseases. In South Asia, particularly in India, the blood fibrinogen level is usually high, owing to high prevalence of CHD or coronary heart diseases and elevated levels of glycoprotein IIb/IIIa which work as a receiver for fibrinogen. Moreover, according to a report by Journal of Thrombosis and Hemostatis, there is a growing emphasis upon the requirement of a controlled and randomized evaluation with clinical result measurement to ascertain that thromboprophylaxis (avoidance of thromboembolic disease or impediment of blood vessels by blood clot) is crucial in joint surgery in Asia. As blood coagulation tests are generally recommended before and after a surgery, escalation in the number of surgeries around the world is expected fuel the light blue tube phlebotomy market during the forecast period.

Key players in the global light blue tube phlebotomy market

Some of the major competitors operating in the global light blue tube phlebotomy market are Greiner BioOne, Medical Expo, CML Biotech Pvt. Ltd., Ajosha BioTeklik Pvt. Ltd., New MicroMed International Pvt. Ltd., FL Medical, Gosselin, and Advacare Pharma.

Click To Reading More On Light blue tube phlebotomy Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Vagus Nerve Stimulators Market - 2019 Global Strategic Business Report

Vagus nerve stimulation (VNS) is a medical treatment in which electric impulses are delivered to vagus nerve for the management and treatment of various types of diseases including epilepsy and depression. Vagus nerve stimulators are devices used to stimulate the vagus nerve with electrical impulses. Vagus nerve stimulators are classified in two types: implantable devices and external devices. An implantable vagus nerve stimulator is a medical device, which is surgically implanted inside the body. External devices are less-invasive, non-surgical vagus nerve stimulators. Various key players in the market are involved in the development of such easy-to-use external vagus nerve stimulators for various indications.

Frequent approval and launch of novel vagus nerve stimulators is expected to drive global vagus nerve stimulators market growth

In July 2017, electroCore, Inc. launched gammaCore (non-invasive vagus nerve stimulator) for acute treatment of pain associated with episodic cluster headache in adult patients in the U.S. gammaCore is a non-invasive, hand-held medical device applied at the neck and sends gentle, patented electrical stimulation through the skin to activate the vagus nerve, resulting in the reduction of pain.

In June 2017, LivaNova Plc. received the U.S. FDA approval for its VNS therapy system for treatment of patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.

The global vagus nerve stimulators market size was valued at US$ 445.1 Mn in 2018, and is expected to witness a CAGR of 9.0% during the forecast period (2018 – 2026).

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2514

High Prevalence of Epilepsy, Depression, and Migraine in Key Regions is expected to Rise Demand for Vagus Nerve Stimulators

Vagus nerve stimulators are widely used in the management and treatment of diseases such as epilepsy, depression, and migraine. High prevalence of such diseases in key regions is expected to drive vagus nerve stimulators market growth over the forecast period. For instance, according to the data published by the National Institute of Mental Health, depression was one of the most common mental disorders in the U.S. in 2016. An estimated 16.2 million adults in the U.S. had at least one major depressive episode. This number represented 6.7% of all the U.S. adults.

Similarly, according to the data published by the World Health Organization in 2018, around 2.4 million people are diagnosed with epilepsy each year, globally. In high-income countries, new cases are between 30 and 50 per 100,000 people, annually.

Asia Pacific is expected to be a Potential Region for Growth of the Vagus Nerve Stimulator Market

LivaNova PLC is one of the leading players in the vagus nerve stimulator market with various products, which earns around 84% of its revenue from the U.S. and rest from other economies. The penetration rate of vagus nerve stimulator is quite low in emerging economies such as Asia Pacific, Middle East, and Africa.

However, high prevalence of migraine, depression, and epilepsy in major economies of Asia Pacific such as China, India, and Australia, and increasing healthcare awareness and expenditure in these economies signifies potential opportunities for vagus nerve stimulators. For instance, according to the data published by the Commonwealth Fund, in 2014, China invested around US$ 992 billion in healthcare, with 30% financed by the central government and local governments and 38% by publicly financed health insurance and private health insurance or social health donations.

Moreover, according to the World Health Organization, 2018, around 3/4th of the population suffering from epilepsy living in low- and middle- income countries do not get the treatment they need, wherein, such medical devices could be used. Manufacturers should collaborate with regional government authorities to spread awareness about these medical devices, as well as increase the number of distributors to cater to the customer base.

Click To Reading More On Vagus Nerve Stimulators Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Ophthalmic Viscoelastic Devices Market Impressively growing Opportunities

Ophthalmic viscoelastic devices (OVD) are basic tools used in modern cataract surgeries. They are non-active, clear, and gel-like solutions with viscous and elastic properties. OVDs mainly contain sodium hyaluronate.

Ophthalmic Viscoelastic Devices Market Impressively growing Opportunities and Global Business Forecast 2026

Ophthalmic viscoelastic devices (OVD) are basic tools used in modern cataract surgeries. They are non-active, clear, and gel-like solutions with viscous and elastic properties. OVDs mainly contain sodium hyaluronate. The viscoelasticity of OVD substance keeps the vitreous face in the proper position and prevents it from flat chambers during surgery. These substances cover and protect the intraocular tissues, ocular structures, and improves visualization. Major role of OVDs is to create and maintain volume in the anterior chamber of the eye and protect the corneal endothelium during particular steps of ophthalmic procedure.

Global Ophthalmic Viscoelastic Devices Market Drivers

The global ophthalmic viscoelastic devices market is expected to witness significant growth due to increasing number of cataract and glaucoma surgeries. Moreover, increasing prevalence of diabetes also contributes to eye disorders. According to WHO, around 422 million people were affected by diabetes worldwide in 2016. Similarly, according to American Academy of Ophthalmology, in 2013, around 48,229 corneal transplants and 2 million cataract surgery in 2014 were performed in the U.S.

Furthermore, education, awareness about eye health, increasing spending power of the populace on healthcare sector, and favorable reimbursements policies in the developed economies also contribute to growth of the OVDs market.

Global Ophthalmic Viscoelastic Devices Market Restraints

However, lack of awareness and ignorance about eye health coupled with high percentage of lower income population in emerging economies who cannot afford cataract or glaucoma surgeries is expected to hamper the market growth. For instance, according to the National Center for Biotechnology Information (NCBI) study of 2010, in Africa, over 40-50% of blindness is due to cataract, affecting around 170,000 people in the region. However, cataract surgical rate among the indigent population is 1,000 per million, annually. Under-developed economies in Africa such as Somalia, Burundi, and Malawi are expected to be a laggards due to poor economic conditions and poor healthcare penetration.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2521

Global Ophthalmic Viscoelastic Devices Market Regional Analysis

North America is expected to hold a dominant position in the global ophthalmic viscoelastic devices market during the forecast period due to increasing expenditure on healthcare in the region. According to the Centers for Medicare & Medicaid Services (CMS), in 2017, the U.S. invested US$ 3.5 trillion in the healthcare sector.

Furthermore, Asia Pacific is the fastest growing market in the global ophthalmic viscoelastic devices market. China and India are the major contributes in the market growth in the region due to increasing geriatric population suffering from cataract. In 2015, the United Nations (UN) reported that India has 8.6% of geriatric population above the age of 60. Moreover, according to China National Committee on Aging (CNCA), China had 17.3% of population above the age of 60 in 2017.

Global Ophthalmic Viscoelastic Devices Market Key Players

Key players operating in the global ophthalmic viscoelastic devices market include, Johnson & Johnson, Alcon Laboratories Inc., Bausch & Lomb, Carl Zeiss AG, Rayner Company, Bohus BioTech AB, and Lifecore Biomedical LLC.

Click To Reading More On Ophthalmic Viscoelastic Devices Market

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Microscopic Polyangiitis Market Modest Situation Among the Top Manufacturers, With Sales

Launch of new treatment methods by key players is expected to drive the global microscopic polyangiitis market growth over the forecast period.

Electrosurgery Accessories Market Growth Analysis, Competitor Landscape

The electrosurgery accessories market revenue is expected to rise, owing to increasing number of new product launches with latest technology.

Electrosurgery Accessories Market Growth Analysis, Competitor Landscape, Opportunity

Electrosurgery accessories are the additional products used in electrosurgical procedures. Electrosurgery is the application of a high-frequency alternating polarity radio wave, this high-frequency waves are used to cut, coagulate, desiccate, or fulgurate biological tissues. The electrosurgery accessories are used in different types of procedures such as gynecological, urological, neurological, and cosmetic surgeries. Pencils, specialty electrodes, return electrodes, suction coagulators, forceps, cords, and adapters are the most commonly used electrosurgery accessories.

The accessories and technologies used in electrosurgeries are minimally invasive with less pain, less blood loss, minimum scarring, and reduced hospital stay. This has resulted in increasing demand for electrosurgical procedures by large patient population. New technological advancements, sophisticated products, and research studies in electrosurgery are highly contributing to the electrosurgery accessories market growth.

Global Electrosurgery Accessories Market: Drivers

The electrosurgery accessories market revenue is expected to rise, owing to increasing number of new product launches with latest technology. For instance, in 2018, Olympus Corporation launched dualknife J endoscopic submucosal dissection (ESD), an electrosurgical knife, which integrates submucosal injection to support efficient, safe, and more reliable ESD performance in short procedure time.

Furthermore, the electrosurgery accessories market size is also increasing due to rising demand for ambulatory surgeries by patients, as ambulatory surgeries involve electrosurgery associated with less pain, less blood loss, minimum scarring, and reduced hospital stay. According to Healthcare Cost and Utilization Project (HCUP) 2014 report, around 11.4 million outpatient surgeries were performed in the U.S. in 2014.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2540

Global Electrosurgery Accessories Market: Restraints

The major restraining factor for electrosurgery accessories market growth is risk of accidents and fire cases due to inadequate knowledge about handling electrosurgery accessories such as specialty electrodes, return electrodes, and suction coagulators. According to the National Center for Biotechnology Information (NCBI) 2016 report, around 57% of surgeons lack adequate knowledge and awareness in managing the equipment in Ireland.

Product recalls due to technical faults is another factor hampering the electrosurgery accessories market size. For instance, in 2018, the U.S. Food and Drug Administration recalled the product bipolar cord from Olsen Medical Group under Class 2 Device Recall, as the product was intruding into the sterile pouch seal during the surgical procedures, thereby increasing the risk of the seal being compromised.

Global Electrosurgery Accessories Market: Regional Analysis

Europe is expected to hold dominant position in the electrosurgery accessories market over the forecast period, owing to the presence of major competitors with new innovative products such as Medtronic PLC, B. Braun Melsungen AG, KLS Martin GmbH & Co. Kg, and Bowa-Electronic GmbH & Co. Kg.

Asia Pacific electrosurgery accessories market size is expected to witness significant growth in future, owing to new product launches in the region for ease of electrosurgical procedures. For instance, in 2018, Integra Lifesciences Holdings Corporation announced the launch of its new CUSA clarity ultrasonic tissue ablation platform in Japan. It is made in combination with ISOCOOL Bipolar Forceps, which as integral part of the product.

Global Electrosurgery Accessories Market: Competitive Landscape

Key players operating in the global electrosurgery accessories market include Medtronic PLC, Olympus Corporation, Conmed Corporation, B. Braun Melsungen AG, Bovie Medical Corporation, Ethicon, Inc. (subsidiary of Johnson & Johnson), Erbe Elektromedizin GmbH, Applied Medical Resources Corporation, Integra Lifesciences Holdings Corporation, KLS Martin Group, Megadyne Medical Products, Inc., and Bowa-Electronic GmbH & Co. Kg.

Click To Reading More On Electrosurgery Accessories Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com